{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16844", "batch_size": 260, "batch_pos": 79, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment discusses a planned trial. 'outbreak scenario' is not high-potency language.", "method": "llm_batch", "batch_id": "batch_2_17052", "batch_size": 260, "batch_pos": 64, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment uses future/hypothetical verbs ('plans to launch', 'respond') without denoting realised impact.", "method": "llm_batch", "batch_id": "batch_3_7540", "batch_size": 260, "batch_pos": 31, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 4, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_4_16496", "batch_size": 260, "batch_pos": 20, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment contains no questions, loaded or otherwise.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_4_16496_r1", "batch_size": 260, "batch_pos": 20, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 5, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_5_16012", "batch_size": 260, "batch_pos": 18, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports a trial plan and a capability ('respond very quickly') but lacks explicit calming language linked to public safety.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_5_16012_r1", "batch_size": 260, "batch_pos": 18, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_16564", "batch_size": 260, "batch_pos": 2, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment states the company 'plans to launch a small human trial... adding Moderna could respond very quickly', not a bare negation of risk or impact.", "method": "llm_batch", "batch_id": "batch_7_9496", "batch_size": 260, "batch_pos": 260, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "regex:CapabilityNoReassurance matched", "method": "regex", "batch_id": "batch_8_16600", "batch_size": 260, "batch_pos": 209, "regex": {"rule": "CapabilityNoReassurance", "span": [72, 79], "captures": []}, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
